Sort
48,018 grants matching “immunotherapy”
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
$513,131J. Silvio Gutkind · University Of California, San Diego · R01 · FY2020 · CA
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer
$513,120Hui-Kuan Lin · Duke University · R01 · FY2025 · CA
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2023 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2022 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2021 · AI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
$513,119Lishan Su · University Of Maryland Baltimore · R01 · FY2024 · AI
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS
$513,111David Reardon · Duke University · P50 · FY2012 · NS
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$513,108Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2022 · NS
Small Circular mRNA Vaccines
$513,077Guizhi Zhu · University Of Michigan At Ann Arbor · R01 · FY2025 · AI
Immunotherapy to Counteract Lethal Doses of Carfentanil
$513,058Kim D Janda · Scripps Research Institute, The · U01 · FY2020 · DA
Gas6:Axl regulation of microglia immune function and Alzheimer's pathogenesis
$512,965Michael Kerry O'Banion · University Of Rochester · R56 · FY2020 · AG
Optimized ultrasound-enhanced immunotherapy
$512,883Katherine W Ferrara · Stanford University · R01 · FY2018 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$512,817Andre Elias Nel · University Of California Los Angeles · R01 · FY2023 · CA
Diabetogenic CD4 T Cell Recognition of Hybrid Peptide Ligands
$512,702Shaodong Dai · University Of Colorado Denver · R56 · FY2020 · AI
Cancer Pharmacology
$512,680Lorraine J Gudas · Weill Medical Coll Of Cornell Univ · T32 · FY2021 · CA
IL-17-driven mechanisms for tumor progression and resistance to therapies
$512,644Thomas Alan Hamilton · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen
$512,642Moonsoo M. Jin · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · CA
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
$512,601Michael Croft · La Jolla Institute For Immunology · R01 · FY2023 · CA
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
$512,601Michael Croft · La Jolla Institute For Immunology · R01 · FY2022 · CA
SUMO Modification and Cancer Therapy
$512,593Yuan Chen · University Of California, San Diego · R01 · FY2025 · CA
SUMO Modification and Cancer Therapy
$512,593Yuan Chen · University Of California, San Diego · R01 · FY2023 · CA
Novel Mutations and Therapy Resistance Mechanisms in Pediatric Cancers
$512,584Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Extrinsic and intrinsic factors regulating commensal-specific T helper-17 cells
$512,561Bei Liu · Medical University Of South Carolina · U01 · FY2017 · AI
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
$512,558Alexander V Ljubimov · Cedars-Sinai Medical Center · R01 · FY2024 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$512,558Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA